# Pharmacogenetic Study in Hepatocellular Carcinoma Patients.

> **NCT05291338** · — · COMPLETED · sponsor: **Rehab Werida** · enrollment: 107 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Lipiodol

## Key facts

- **NCT ID:** NCT05291338
- **Lead sponsor:** Rehab Werida
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-04-01
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05291338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05291338, "Pharmacogenetic Study in Hepatocellular Carcinoma Patients.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05291338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*